Abbreviations. PD = Parkinson's disease, LRRK2 = Leucine-rich repeat kinase 2, AAO = age at onset, DNM3 = Dynamin 3, KASP = 'Kompetitive' allele-specific polymerase chain reaction, MAF = minor allele frequency, GWAS = Genome-wide association study, SNP = single nucleotide polymorphism Abstract Objective: To assess the reported LRRK2 age-at-onset (AAO) modifier DNM3 rs2421947, and the proximate genome wide association signal VAMP4 rs11578699 on AAO of Parkinson's disease (PD), with rare (rs34637584; p.G2019S) or common risk factors (rs10878226) in the LRRK2 locus.
Introduction
The p.G2019S coding variant in the LRRK2 gene is the most common high penetrance mutation causing parkinsonism. The mutation occurs in 1-40% of PD cases, varying by ethnicity (1) . LRRK2 parkinsonism is broadly similar to "idiopathic" disease in clinical manifest-ations and age at onset (AAO), generating interest in its potential as a therapeutic target with broader application to PD (2) . In addition to rare pathogenic mutations, genome wide association studies (GWAS) show that common variation in LRRK2 is a risk factor for sporadic PD (3) (23) .
There is a wide range in PD AAO among p.G2019S carriers. It is estimated that the heritability of PD AAO (~0.11) is lower than the overall heritability of risk for PD (~0.27) (4) . Currently the strongest genetic association with AAO is through genetic risk score (GRS) . There is overlap between the heritability of risk, as quantified in the GRS, and AAO. As LRRK2 is a functionally complex protein with many protein-protein interaction domains, there may be diverse genetic modifiers that vary in effect size and frequency.
Trinh, Gustavsson and colleagues (5) presented evidence of modification by a common variant haplotype tag in DNM3 (rs2421947; minor allele frequency (C) = 0.4), for which the median onset of LRRK2 parkinsonism for GG homozygotes was 12·5 years younger than that of CC homozygotes (direction of effect GG < GC < CC).
Fernandez-Santiago, Garrido (6) observed a consistent trend for the rs2421947 G allele on AAO in LRRK2 p.G2019S carriers, with median onset 3 years younger in patients with the G allele, though the result was not significant. In the largest GWAS metaanalysis of idiopathic PD the nearby VAMP4 gene variant rs11578699, located 113,325 bp from DNM3 rs2421947, emerged as a statistically significant PD risk association, raising the possibility the effect DNM3 may relate to linkage disequilibrium with VAMP4 (7) . LRRK2 has a role in both monogenic and idiopathic forms of PD and overlap in genetic modifiers may exist.
We investigated the impact of DNM3 rs2421947 and VAMP4 rs11578699 on AAO in a large multi-ethnic cohort of European, North African, and Ashkenazi Jewish LRRK2 p.G2019S carriers and a larger cohort of European patients with and without the LRRK2 common risk allele.
Methods

Data collection
Patient cohorts: LRRK2 p.G2019S heterozygotes were identified from cohorts in the Data from two published studies analysing DNM3 rs2421947 and LRRK2 p.G2019S parkinsonism with AAO was also included comprising 754 participants (5, 6) . All studies willing to participate and currently holding minimum required data for LRRK2 p.G2019S carriers were included: PD onset age or sampling age for asymptomatic carriers; and DNM3 rs2421947 or a high RSQ proxy SNP. Where these studies had also genotyped VAMP4 rs11578699 or a high RSQ proxy, these data were also included in the analysis of the VAMP4 gene (n=786). Patients with PD without a known Mendelian or high risk genetic cause of disease were collated from the UK-wide Tracking Parkinson's study (8) and from IPDGC datasets. Summary statistics for DNM3 rs2421947 and VAMP4 rs11578699 were obtained from the most recent large-scale PD GWAS (7) and PD AAO GWAS (4) . All studies were approved by each respective institutional ethics review committee and all participants provided written informed consent. All studies were carried out in accordance with the Declaration of Helsinki (9) .
Genetic analyses:
Genotyping was performed on different platforms (Neurochip array, NeuroX array, TaqMan assays, Infinium OmniExpress-24, and Illumina HumanCore Exome array) at participating centres. The LRRK2 p.G2019S mutation was directly genotyped. Sanger sequence or KASPar verification of the DNM3 rs2421947 variant was carried out on data subsets at study specific centres. Where the variant DNM3 rs2421947 was imputed, only RSQ values above 0.85 were used, and only RSQ values above 0.75 were used for VAMP4 rs11578699 (table-e1), as the RSQ quality of available data for variants VAMP4 rs11578699 was lower. 1478 LRRK2 p.G2019S carriers were identified across study cohorts. 2052 samples from patients with idiopathic PD from the Tracking Parkinson's disease study passed quality control and had no identified genetic cause of disease (8) . 96 patients with PD were excluded due to missing AAO data; therefore 1956 patients with PD and without LRRK2 p.G2019S
were included in further analysis. Summary statistics and patient data from the most recent PD GWAS included over 37.7K cases, 18.6K 'proxy-cases' and 1.4M controls.
The most recent PD AAO GWAS included data from 28.6K patients (4, 7) .
Statistical analyses:
Data from the studies were pooled. We calculated Hardy-Weinberg Equilibrium (HWE) for VAMP4 rs11578699 and DNM3 rs2421947 in p.G2019S carriers. QC HWE for iPD and controls is summarised in the recent largescale PD GWAS. We assessed linkage disequilibrium (LD) measures RSQ and D' between DNM3 rs2421947 and VAMP4 rs11578699 in different populations to evaluate the possibility that an extended haplotype block might explain the relationship between genotypes. We meta-analysed DNM3 rs2421947 data from all previously unpublished datasets using Cox proportional hazards (figure 2A) and linear regression models (figure 2B). We pooled these data with previously published data and meta-analysed again with the same methods (figure 2C and D). We then analysed VAMP4 rs11578699 impact on AAO with Cox proportional hazards and linear regression (figure 2E and F).
Finally we analysed the impact of VAMP4 rs11578699 on AAO in idiopathic PD carrying the LRRK2 rs10878226 variant. LRRK2 rs10878226 has also been implicated in PD risk (odds ratio [OR], 1.20; 95% confidence interval [CI], 1.08-1.33; p = 6.3× 10−4 , n=6129)
(3).
Gene expression: Gene expression profiles of DNM3 rs2421947 and VAMP4
rs11578699 were assessed using publicly available Web-based resources: BRAINEAC (www.braineac.org) (11); GTEx (www.gtexportal.org); and Allen Brain Atlas (www.brainmap.org) (12) , and evaluated based on the significance level required for inclusion in colocalization (COLOC) analysis (appendix e-1).
Results
DNM3 rs2421947 and AMP4 rs11578699 and VAMP4 rs11578699 genotypes were in Hardy-Weinberg equilibrium in controls.
There was no LD between DNM3 rs2421947 and VAMP4 rs11578699, as assessed through RSQ and D', within or across population samples, indicating that these are independent variants (table e-2)
We investigated the possibility that ethnic variation in allele frequency might explain a variable effect of DNM3 on affected LRRK2 penetrance. Aside from the Norwegian cohort DNM3 rs2421947 MAF (C) of 0.69 (vs. other Europeans p=0.00012), all DNM3 rs2421947 MAF in the study were between 0.43-0.51 (table 1) . There was no difference between Ashkenazi Jews and European frequencies (p=0.94); or between Ashkenazi Jews and North Africans (p=0.28); nor between Europeans and North Africans (p=0.54) at this locus. Publicly available allele frequencies (http://gnomad.broadinstitute.org ) were similar (table 1) . VAMP4 rs11578699 MAF were between 0.15-0.30 in different populations.
We assessed possible association between these variants and LRRK2 p.G2019S patients, and between these variants and idiopathic PD. There was no association between DNM3 rs2421947 and p.G2019S genotype in all PD cases (p=0.42). There was no difference in allele frequencies between patients with PD and asymptomatic heterozygotes (p=0.056). When the original discovery data was meta-analysed with data from this study there was a significant association between DNM3 rs2421947 and PD affected status in p.G2019S heterozygotes (p=3.1x10 -5 ). In the most recent PD GWAS there was no genome-wide significant association between DNM3 rs2421947 and PD (p=0.0051). There was no association between VAMP4 rs11578699 and LRRK2 p.G2019S status in European PD (p=0.60) and no difference in VAMP4 rs11578699 MAF between LRRK2 p.G2019S patients and asymptomatic carriers (p=0.64). Mean sampling age for p.G2019S heterozygotes without PD was 56 years across ethnicities; 63 years in AJ subjects; and 56 years for Europeans. Figure 1A) , and LRRK2 p.G2019S carriers ( Figure 1B-D) . The same method was also used to visualise risk for VAMP4 rs11578699 genotypes in individuals with LRRK2 p.G2019S ( Figure 1E and F). We carried out a multi-ethnic meta-analysis of newly contributed data of DNM3 rs2421947 GG versus CC and CG genotypes against onset age in 724 LRRK2 p.G2019S carriers, using a random effects model on disease-free survival. DNM3
rs2421947 did not significantly affect the age associated hazards of developing parkinsonism (hazard ratio [HR] 1.09, 95% CI 0.95-1.25, p = 0.20, n=724), as shown in Figure 2 . I 2 heterogeneity was <0.01% (p = 0.42). Linear regression meta-analysis on PD AAO was not significant (beta = -1.19, p = 0.55, n =1304), though I 2 heterogeneity was 86.9%, p < 0.01. The impact of GG versus CC and CG was not significant in subgroup analyses (figure 2).
When our new data was pooled with the two previous studies and meta-analysed, there was a significant but small effect of DNM3 rs2421947 on AAO in LRRK2 p.G2019S parkinsonism ([HR] 1.14, 95% CI, 1.02-1.27, p = 0.025, n = 1478). I 2 total heterogeneity was 22.8%, p=0.37. However, linear regression meta-analysis of LRRK2 p.G2019S
AAO was not significant (beta = -2.21, p = 0.083, n = 1304). I 2 total heterogeneity for linear regression meta-analysis was 82.3%, p<0.0001 (figure 2).
Meta-analysis of VAMP4 rs11578699 impact on AAO in LRRK2 p.G2019S parkinsonism was not significant for CC versus TT and TC genotypes (hazard ratio [HR]
1.02, 95% CI 0.88-1.17, p = 0.84, n=786); (beta = -0.25, p=0.75, n=756).
We Finally, we investigated the possibility that might be an interaction between the GWAS defined common LRRK2 risk allele (rs10878226), and DNM3 and VAMP4. We analysed 4882 cases with PD carrying the LRRK2 risk variant minor allele using linear regression of AAO and plotting of the Kaplan Meier curve, as shown in Figure 3 . TT versus TC and CC VAMP4 rs11578699 genotype was significantly associated with AAO risk in this cohort (beta=1.68, se=0.81, p=0.037, n=4882). VAMP4 rs11578699 was not significantly associated with AAO risk in idiopathic PD cases without the LRRK2 rs10878226 risk variant (beta=-0.28, se=0.48, p=0.56, n=14970). Far fewer patients with idiopathic PD had been genotyped for DNM3 rs2421947 in the PD GWAS cohort (table 1), meaning we were not able to assess interaction between DNM3 and the LRRK2 risk allele.
Figure 3. Kaplan Meier analysis by VAMP4 rs11578699 genotype in PD cases carrying LRRK2 risk variant (rs10878226)
We then reviewed VAMP4 and DNM3 human brain gene expression and co-expression data from the BRAINEAC 23 (11) , GTEx, and Allen Atlas databases (12) (figure e-3).
VAMP4 rs11578699 is an eQTL for VAMP4 expression: NES: 0.29, p = 3.5x10 -9
(cerebellum, GTEx database); NES: 0.32, p = 6.5x10 -7 (cerebellar hemisphere, GTEx database). Cerebellum expression data for rs11578699 exceeds the significance level required for inclusion in COLOC analysis: p = 5x10 -8 . DNM3 rs2421947 did not appear to be an eQTL for DNM3 expression in the brain in the GTex database, though VAMP4
and DNM3 gene expression in brain were high (figure e-3).
Discussion
We have analysed the effect of DNM3 rs2421947 on AAO in LRRK2 p.G2019S
parkinsonism. In the original discovery analysis, there was a difference of 12.5 years between DNM3 rs2421947 GG and CC genotypes. When all available data was analysed together there was a small effect of DNM3 rs2421947 on AAO. However, (meta-)analysis of independent multi-ethnic series did not identify a significant difference between genotypes. Consistent with the recent AAO GWAS (4), our study indicated that DNM3 rs2421947 does not affect AAO in non-p.G2019S disease.
Analysis of carriers of a common LRRK2 risk SNP provided support for a potential interaction between VAMP4 and LRRK2, which requires replication in larger sample sizes. Gene expression analysis indicated that VAMP4 rs11578699 is an eQTL for VAMP4 expression. One possibility for the lack of replication of DNM3 modification of p.G2019S AAO is that heterogeneity in the sample may limit the observed effect in the meta-analysis; this has previously led to non-replication in independent samples in genome-wide association studies (13) (14) . Significant heterogeneity was observed in the linear regression meta-analysis.
Minor allele frequencies across the cohort in different populations were similar, making it less likely that spurious association due to population stratification had occurred. The impact of DNM3 may vary between ethnicities and the strongest effects were seen in Ashkenazi Jewish p.G2019S carriers (MAF was also slightly higher in AJ than in European p.G2019S cases), although not reaching significance (Figure 2 There appears to be a reduction in penetrance for Ashkenazi Jewish LRRK2 p.G2019S
carriers as compared to European LRRK2 p.G2019S carriers, which is also apparent in our data. These data imply that there may be potential protective factors in the relatively homogeneous Norwegian and Ashkenazi Jewish population and that ethnic and population effects are likely to be very important in analysing this variant. Our analysis and comparison of background allele frequencies in this study suggest that this is unlikely to primarily relate to the VAMP4 and DNM3 variants that we have studied.
However there may be other rare variant effects that will emerge with fine mapping of this region. analysis of VAMP4 and DNM3 expression indicated that both are highly expressed in the brain, though these are not in LD and likely represent independent signals.
Variation in this genetic region may have important implications for the treatment of PD. 
Supplementary material
Gene Expression
The BRAINEAC database hosts data on brain tissues (frontal cortex, temporal cortex, parietal cortex, occipital cortex, hippocampus, thalamus, putamen, substantia nigra, medulla, cerebellum, and white matter) from 134 healthy controls. The GTEx database consists of 8555 samples from 53 tissues (including 13 brain regions) from 544 donors.
The Allen Human Brain Atlas database microarray data is from 8 neuropathologically normal individuals of varying ethnicity, and covers ~150 brain regions. Uncorrected for multiple testing c There are insufficient p.G2019S carriers in these categories for the t test to be calculated.
Comparison of datasets
We analysed the discovery data and subsequent cohorts separately (GG versus CC and CG as described previously). There was a strong association between rs2421947
and PD AAO in discovery data (hazard ratio [HR] 1.59, 95% CI 1.28-1.97, p<0.001).
This was also present through linear regression analysis (beta = -4.93, p = 0.00019).
